PDCD1 and non-small cell lung carcinoma: We enrolled 40 previously untreated patients with NSCLC undergoing this regimen to assess the potential of TATAN‐activated peripheral ETAST levels as biomarkers for predicting the efficacy of PD‐1 inhibitors combined with chemotherapy in NSCLC treatment.